Workflow
iStent
icon
Search documents
舍弃CUDA编程!CMU等用几十行代码将LLM编译成巨型内核,推理延迟可降6.7倍
机器之心· 2025-06-21 01:33
机器之心报道 编辑:杜伟 在 AI 领域,英伟达开发的 CUDA 是驱动大语言模型(LLM)训练和推理的核心计算引擎。 MPK 的易用性很强,你只需要几十行 Python 代码就能将 LLM 编译成一个高性能巨型内核,实现快速推理,整个过程无需 CUDA 编程。 不过,CUDA 驱动的 LLM 推理面临着手动优化成本高、端到端延迟高等不足,需要进一步优化或者寻找更高效的替代方案。 近日,CMU 助理教授贾志豪(Zhihao Jia)团队创新玩法,推出了一个名为 「Mirage Persistent Kernel(MPK)」的编译器,可以自动将 LLM 转化为优化的巨型 内核(megakernel),从而将 LLM 推理延迟降低 1.2 到 6.7 倍。 MPK 将 LLM 推理延迟推近硬件极限。在单个 A100-40GB GPU 上,MPK 将 Qwen3-8B 每个 token 的延迟从 14.5 毫秒 (vLLM/SGLang) 降低到 12.5 毫秒,逼近基于 内存带宽计算得出的 10 毫秒理论下限。 GitHub 地址:https://github.com/mirage-project/mirage/ ...
Glaukos (GKOS) 2025 Conference Transcript
2025-06-04 13:47
Summary of Glaukos (GKOS) 2025 Conference Call Company Overview - **Company**: Glaukos Corporation (GKOS) - **Industry**: Medical Supplies and Devices, specifically focused on glaucoma treatment Key Points and Arguments Interventional Glaucoma Paradigm Shift - The interventional glaucoma approach is gaining acceptance as a proactive method to manage glaucoma, moving away from traditional drop treatments which patients often neglect [3][4] - The company emphasizes the need for changing practice patterns and educating healthcare providers to adopt this new approach effectively [5][6] - The transition to an interventional approach is expected to take about ten years, with a focus on improving patient outcomes [6] Physician Adoption and Challenges - Physician receptiveness varies, but the main challenge lies in translating positive clinical feedback into actionable changes in practice [7][8] - The company is focused on addressing operational challenges within practices, such as educating referral networks and changing administrative processes [9] Market Dynamics and Treatment Modalities - The company acknowledges the competition from other treatment modalities like SLT and emphasizes the importance of interventional approaches in patient care [12][16] - The average patient remains in care for over 20 years, necessitating multiple interventions to manage their condition effectively [17] iDose Product Launch and Reimbursement - The iDose product has seen successful launch and is currently focused on securing reimbursement from various Medicare Administrative Contractors (MACs) [18][19] - The reimbursement landscape is segmented into three tiers, with varying levels of predictability and success in claims processing [19][20] - The company is actively working to streamline reimbursement processes and is optimistic about future growth in iDose contributions [26][27] Financial Performance and Cash Flow - The company aims to achieve cash flow breakeven in the near term, with expectations that iDose will contribute positively to gross margins over time [41][42] - Operating expenses are growing at a slower rate than revenue, indicating operational leverage is being achieved [45] Sales Strategy and Market Access - The sales force is deemed sufficient, with plans to fill geographic gaps as needed [47] - The company is focusing on supporting healthcare providers in navigating the complexities of commercial payer systems, which differ significantly from Medicare processes [36][37] Future Outlook and Growth Potential - The company anticipates continued growth in the MIGS market, with expectations of mid-single-digit growth rates in the long term [57][58] - The focus remains on increasing standalone utilization of iDose and other products, which may influence market dynamics and physician preferences [58] Additional Important Insights - The company is investing in educational initiatives and industry collaborations to promote best practices in interventional glaucoma [11] - The reimbursement process is described as a data collection effort by MACs to ensure medical necessity and appropriate payment calculations [23][24] - The company is also working on new product developments, including the Trio system, which aims to enhance in-office procedures [50][51] This summary encapsulates the key discussions and insights from the Glaukos conference call, highlighting the company's strategic focus on interventional glaucoma, product launches, and market dynamics.
Glaukos (GKOS) FY Conference Transcript
2025-06-03 18:40
Glaukos (GKOS) FY Conference June 03, 2025 01:40 PM ET Speaker0 How's it going, everyone? I'm gonna step in. My name is Macaulay Cobain. I work under Margaret Kayser covering med tech. We're gonna have Glaukos present for us. We have management with us today. You can go to WilliamBlair.com for a full list of our disclosures, and we'll, we'll have Alex kick it off here. Speaker1 Alright. Thank you all for coming and joining us, this afternoon and to talk a little bit about Glaukos. My pleasure to, speak to y ...
Here's Why You Should Retain Glaukos Stock in Your Portfolio
ZACKS· 2025-05-21 12:20
Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 34.9% so far this year compared with the industry’s 7.5% decline. The S&P 500 Index has increased 0.7% in the same time frame.Glaukos, with a market capitalization of $5.48 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-q ...
Z Product|全球最佳产品(2.24-3.2),两个华人团队位居前三
Z Potentials· 2025-03-06 06:36
2.24-3.2 TOP10 | | Best of the week of February 24, 2025 Daily | Weekly | Monthly | Yearly | Featured | All | | --- | --- | --- | --- | --- | --- | --- | | 1 | 1月 27—2月 2 2月 3—9 2月 10-16 | 2月 17—23 | | | 2月 24-3月 2 | 1 | | | OpenArt Consistent Characters | | | | Q | 0 | | | Craft your characters and stories with ease | | | | 163 | 1,419 | | | Art · Artificial Intelligence · Community | | | | | | | | Basalt | | | | D | 0 | | | Integrate Al in your product in seconds | | | | 229 | 1,311 | | | Productivity · S ...